Seaport Therapeutics heads into its September 4 earnings event with the lending market completely exhausted and a fresh analyst initiation landing this week — a rare combination of maximum short pressure and growing Street conviction on the same name.
The borrow situation is about as tight as it gets. Availability has collapsed to just 0.08% of shares outstanding — effectively zero, meaning virtually every share in the lending pool is already lent out. That has been the picture for most of August. Before August 14, availability sat in the 7–19% range. Then it evaporated almost overnight, and has barely budged since, with the 52-week minimum for availability at 0.05%. Cost to borrow has been running in a narrow 6–7% band throughout the month, edging up slightly to 6.49% this week. That stability in borrowing costs, even as availability collapsed, suggests the demand for shorts and the existing borrowed inventory reached an equilibrium — but there is essentially no slack left for new short positions to be established.
Short interest itself tells the other side of the crowding story. Shares short have climbed roughly 41% over the past month to approximately 3.26 million shares. The float percent of short interest is unavailable in the current snapshot, but the raw build is notable. The ORTEX short score has risen to 87.2 — up from 82.9 two weeks ago — placing well into the top decile of bearish short-positioning signals across the universe. Bears see a pre-revenue biotech burning cash, with no commercial product until 2030 at the earliest, competing in a crowded neuropsychiatric space where unproven platform technology carries real regulatory risk.
The Street is reading it differently. All five analysts covering the stock carry Buy-equivalent ratings, with a mean price target of $37.00 against Tuesday's close of $24.83 — roughly 49% implied upside. Jones Trading initiated coverage this week with a Buy and a $32 target, adding to the chorus. HC Wainwright has held a $50 target through multiple reiterations. JPMorgan came in at $42 when it initiated in May. The bull case centres on the Glyph drug-delivery platform, which aims to improve bioavailability and tolerability of existing compounds, with lead programs targeting cluster headaches and addiction. CEO Daphne Zohar — herself holding over 2% of shares — is viewed by bulls as a significant credibility asset. The price-to-book multiple has expanded roughly 27% over the past 30 days as the stock rallied 18% in August, though the EV/EBITDA and PE ratios remain deeply negative, as expected for a clinical-stage name.
Institutional ownership reinforces the concentrated, high-conviction nature of the shareholder base. PureTech Health holds 31% of shares, Arch Venture Partners 12%, and General Atlantic a further 11%. Notably, Arch Venture Partners itself bought 1.1 million shares at $18 in May — a $19.8 million insider purchase that now sits well in the money. A director added 13,000 shares in late June. Net insider buying over the trailing 90 days totals over $20 million on shares. That is not the signature of a group expecting imminent dilution.
The two most recent earnings prints both produced positive stock moves — up 4.7% on the day and up 12.5% over the five days following August 2026 results, and up 7.4% on the day in June. With short availability at essentially zero and another catalyst arriving September 4, the setup heading into that print is the dynamic worth watching most closely.
See the live data behind this article on ORTEX.
Open SPTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
